An update from Shield Therapeutics ( (GB:STX) ) is now available.
Shield Therapeutics reported significant financial growth in 2024, with net revenues reaching $32.3 million, driven by a 153% increase in ACCRUFeR® revenues. The company also strengthened its balance sheet with a $10 million equity funding, aiming to achieve cash flow positivity by the end of 2025. Operationally, Shield expanded its global reach with ACCRUFeR®, securing approvals and launching in new markets such as Canada, and progressing regulatory filings in Korea and China. The company also completed a Phase 3 pediatric study, confirming the efficacy and safety of its pediatric formulation.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency with its innovative product, ACCRUFeR®/FeRACCRU® (ferric maltol). The company collaborates with Viatris Inc. in the U.S. and has licensing agreements with various pharmaceutical companies for markets outside the U.S., including Europe, China, Korea, and Canada.
YTD Price Performance: -12.96%
Average Trading Volume: 2,551,016
Technical Sentiment Signal: Buy
Current Market Cap: £25M
For a thorough assessment of STX stock, go to TipRanks’ Stock Analysis page.